Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
-
Published:2023-11-24
Issue:12
Volume:37
Page:1069-1080
-
ISSN:1172-7047
-
Container-title:CNS Drugs
-
language:en
-
Short-container-title:CNS Drugs
Author:
Caponnetto Valeria, Russo Antonio, Silvestro Marcello, Tessitore Alessandro, De Icco Roberto, Vaghi Gloria, Sances Grazia, Tassorelli Cristina, Baraldi Carlo, Castro Flavia Lo, Guerzoni Simona, Prudenzano Maria Pia, Fallacara Adriana, Gentile Martino, Ornello Raffaele, Onofri Agnese, Burgalassi Andrea, Chiarugi Alberto, De Cesaris Francesco, Granato Antonio, Casalena Alfonsina, De Tommaso Marina, Mampreso Edoardo, Merlo Paola, Coppola Gianluca, Battistini Stefania, Rebecchi Valentina, Rainero Innocenzo, Sepe Federica Nicoletta, Dalla Volta Giorgio, Sacco Simona, Geppetti Pierangelo, Iannone Luigi FrancescoORCID, Allena Marta, Brovia Daria, Liaci Giorgio, Tabasso Giorgio, Vigani Giulia, Garascia Gabriele, Manganotti Paolo, La Porta Anna, Beretta Natascia, Tronci Stefano, Baiata Claudio,
Funder
Università degli Studi di Firenze
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference24 articles.
1. Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol. 2022;21(3):284–94. 2. Bigal ME, Walter S, Rapoport AM. Fremanezumab as a preventive treatment for episodic and chronic migraine. Expert Rev Neurother. 2019;19(8):719–28. 3. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. 4. Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030–40. 5. Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. 2021;22(1):68.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|